Accessibility Accessibility Accessibility for Ontarians With Disabilities Act (AODA) Accessibility for Ontarians With Disabilities Act (AODA) Osteoporosis Canada is committed to excellence in servicing all customers including people with disabilities. […]

Dairy, soy, and risk of breast cancer: those confounded milks https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyaa007/5743492#199259276 Dairy, soy, and risk of breast cancer: those confounded milks Gary E Fraser, Karen Jaceldo-Siegl, Michael Orlich, Andrew Mashchak, Rawiwan Sirirat, Synnove Knutsen International […]

Our Leadership Our Senior Team Meet the members of the Senior Team at Osteoporosis Canada who are committed and passionate about their work in creating a Canada without osteoporotic fractures […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada – Updated August 6, 2013 Calcitonin is a hormone found naturally in our bodies. A synthetic form […]

Osteoporosis Canada (OC) is pleased to announce the updated version of “Key performance indicators (KPIs) for Canadian FLSs (v2.0)”. Version 2 of the OC FLS KPIs brings in new learnings […]

Latest News PHAC Osteoporosis Key Findings August 18, 2021 Osteoporosis Canada has been working closely with the Public Health Agency of Canada (PHAC) over the past few years assisting in […]

SERMS Selective Estrogen Receptor Modulators Raloxifene (Evista®) is from a family of drugs called SERMs (Selective Estrogen Receptor Modulators). How Does Raloxifene Work? During their reproductive years, women produce significant […]

The Accessible Canada Directorate within Employment and Social Development Canada (ESDC) has engaged Quorus Consulting Group to conduct the second cycle of public opinion research measuring Canadians’ awareness and experience(s) […]

Osteoporosis Canada is saddened to announce the passing of Dr. Timothy M. Murray, founding member of Osteoporosis Canada. Dr. Murray was the Emeritus Professor of Medicine at the University of […]